Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist: Hyperkalaemia
Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in hyperkalaemia compared with selective aldosterone antagonist (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist Hyperkalaemia · proteinuric chronic kidney disease Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in hyperkalaemia compared with selective aldosterone antagonist (low certainty). Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression… (2020) · Cochrane Headline outcomes only | RR 0.89 [0.45, 1.77] | 1 study · 1023 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.